The average selling price for ATELLICA in the Netherlands dropped in 2022, according to GlobalData. The average selling price, the complete price range of high and low prices and a 3-year forecast for the ATELLICA device in the Netherlands can be viewed in GlobalData’s micro pricing report. Buy the report here.
The ATELLICA is sold by Siemens Healthineers in the Procalcitonin Tests market. The procalcitonin (PCT) in vitro diagnostic device determines the quantity of PCT in the blood. Our blood typically contains relatively lower levels of PCT. However, PCT can be released into the bloodstream by cells in many different parts of the body in response to a major bacterial infection. A significant infection or sepsis may therefore be indicated by a high level of PCT in the blood. The chemiluminescence enzyme immunoassay (CLEIA) is the predominant method employed for detecting PCT in patient samples. Other test types used to measure PCT include fluorescence immunoassays, latex enhanced immunoturbidimetric assays, and lateral flow immunochromatographic test strips.
Factors contributing to the list price of a medical device include but are not limited to therapy area, complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. Moreover, final selling prices vary geographically and by facility type. These prices are further subject to discounts, as well as purchasing and distribution agreements.
For a complete picture of Siemens Healthineers’ Procalcitonin Tests device pricing in the Netherlands, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.